Archived explainer. For the current picture see today's CAPR page.
CAPRICOR THERAPEUTIC (CAPR) is drawing unusual attention today. Our newswire has captured 15 stories on CAPR across 9 sources in the last 36 hours, with AI sentiment reading bearish (avg 39/100).
CAPR stock is moving sharply lower today, having fallen more than 63% in the last eight sessions as the FDA released briefing documents ahead of an advisory committee meeting on Deramiocel. The documents have raised concerns about the drug’s effectiveness in treating cardiomyopathy in Duchenne muscular dystrophy patients, leading to a wave of downgrades and skepticism from analysts.
The FDA’s briefing documents, released on Monday, highlighted what it described as an inability to identify a subpopulation of Duchenne muscular dystrophy patients who might benefit from Deramiocel. Capricor responded by calling the FDA’s analysis “obsolete,” emphasizing the strength of its clinical data. This back-and-forth has intensified uncertainty around the drug’s approval prospects. B. Riley downgraded the stock on FDA briefing concerns, while H.C. Wainwright maintained a Buy rating with a $60 price target. The mixed analyst reactions reflect a deep divide in how the data is being interpreted.
Retail traders on r/wallstreetbets are calling the stock oversold, but institutional sentiment has turned cautious. Capricor’s CFO and other executives sold shares in recent days, adding to the negative momentum. The stock is now trading near a 52-week low of $6.99, down from $19.12 just eight sessions ago.
The stock has seen a dramatic price decline, with volume significantly above its 30-day average. Over the past 30 days, insiders have sold four times totaling $1.5 million, with no insider purchases recorded. The stock has a beta of 0.42, suggesting it is less volatile than the broader market, but the recent move defies that pattern. The 52-week range of $4.30 to $40.37 shows a high degree of price fluctuation, consistent with a speculative biotech stock. The stock’s market cap is $1.1 billion, and the company remains unprofitable with a TTM EPS of -2.32 and revenue down 52.1% year-to-date.
The FDA advisory committee meeting is the key event to watch. If the panel recommends approval, the stock could see a sharp rebound. Investors should also monitor the breadth of analyst coverage and any additional insider transactions in the coming days.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Not financial advice.
Wall Street turned more cautious, with Roth, B. Riley and Cantor flagging elevated approval risk.
The documents released by the FDA on Monday, ahead of an advisory committee meeting to review Capricor’s application for Deramiocel, have raised a divide among Wall Street experts over what to expect.
Capricor Therapeutics stock falls after FDA briefing ahead of AdCom
H.C. Wainwright reiterates Capricor stock Buy rating at $60 target
B.Riley downgrades Capricor stock on FDA briefing concerns
The FDA released briefing documents, raising concerns over whether Capricor’s lead therapy, Deramiocel, has demonstrated sufficient effectiveness in treating cardiomyopathy in patients with Duchenne muscular dystrophy.
Capricor Therapeutics responds publicly to FDA briefing materials ahead of an influential advisory committee meeting, emphasizing the strength of its Deramiocel clinical results for Duchenne muscular dystrophy. The company highlights its adherence to final analysis protocols and addresses confusion about differing analysis plans referenced by the FDA.
In the briefing documents for the meeting released Monday, the FDA said its reviewers were unable to identify a DMD subpopulation that may potentially derive benefit from deramiocel after extensive analyses of the data in the original application and the resubmission, adding that "the benefit-risk assessment for deramiocel appears unfavorable in the absence of evidence of effectiveness."
More on CAPR: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier CAPR move explainers: 2026-07-29 · 2026-07-28 · 2026-07-27